These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32103362)

  • 41. Steroids and macular edema from retinal vein occlusion.
    Glacet-Bernard A; Coscas G; Zourdani A; Soubrane G; Souied EH
    Eur J Ophthalmol; 2011; 21 Suppl 6():S37-44. PubMed ID: 23264327
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion.
    Loukianou E; Brouzas D; Chatzistefanou K; Koutsandrea C
    Int Ophthalmol; 2016 Feb; 36(1):21-36. PubMed ID: 25820576
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion].
    Schaal KB; Höh AE; Scheuerle A; Schütt F; Dithmar S
    Ophthalmologe; 2007 Apr; 104(4):285-9. PubMed ID: 17372737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Central retinal vein occlusion: A patient with systemic sclerosis.
    Karadžić J; Radosavljević A; Kovačević I
    Vojnosanit Pregl; 2016 Sep; 73(9):868-72. PubMed ID: 29320621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
    Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
    Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion.
    Patel PJ; Zaheer I; Karia N
    Eye (Lond); 2008 Jan; 22(1):60-4. PubMed ID: 16902493
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study.
    Georgalas L; Tservakis I; Kiskira EE; Petrou P; Papaconstantinou D; Kanakis M
    Cutan Ocul Toxicol; 2019 Dec; 38(4):330-337. PubMed ID: 31060385
    [No Abstract]   [Full Text] [Related]  

  • 49. Intravitreal Bevacizumab for Traumatic Choroidal Rupture.
    Kim M; Kim JH; Seo Y; Koh HJ; Lee SC
    Optom Vis Sci; 2015 Oct; 92(10):e363-7. PubMed ID: 26367340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined treatment with intravitreal bevacizumab and laser photocoagulation for exudative maculopathy in facioscapulohumeral muscular dystrophy.
    Matos R; Beato J; Silva M; Silva S; Brandão E; Falcão-Reis F; Penas S
    Ophthalmic Genet; 2017; 38(5):490-493. PubMed ID: 28121209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
    Ehlers JP; Decroos FC; Fekrat S
    Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of immediate versus deferred intravitreal Bevacizumab in macular oedema due to branch retinal vein occlusion: a pilot study.
    Khan MA; Mallika V; Joshi D
    Int Ophthalmol; 2018 Jun; 38(3):943-949. PubMed ID: 28432581
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Recurrence of macular edema complicating central retinal vein occlusion: Consider follow-up fluorescein angiography].
    Baba A; Miri A; Guillaumie T; Zongo PD
    J Fr Ophtalmol; 2020 Apr; 43(4):305-311. PubMed ID: 32087984
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spectral domain optical coherence tomography evolutive features in acute macular neuroretinopathy.
    Azar G; Wolff B; Cornut PL; Sahel JA; Mauget-Faÿsse M
    Eur J Ophthalmol; 2012; 22(5):850-2. PubMed ID: 22610717
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced depth imaging OCT and indocyanine green angiography changes in acute macular neuroretinopathy.
    Sanjari N; Moein HR; Soheilian R; Soheilian M; Peyman GA
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(6 Suppl):S36-9. PubMed ID: 24220882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-VEGF therapy for central retinal vein occlusion caused by tuberculosis-associated uveitis: a case report.
    Taguchi M; Sakurai Y; Kanda T; Takeuchi M
    Int Med Case Rep J; 2017; 10():139-141. PubMed ID: 28458584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Macular hole formation following intravitreal injection of ranibizumab for branch retinal vein occlusion: a case report.
    Muramatsu D; Mitsuhashi R; Iwasaki T; Goto H; Miura M
    BMC Res Notes; 2015 Aug; 8():358. PubMed ID: 26285577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.
    Januschowski K; Feltgen N; Pielen A; Spitzer B; Rehak M; Spital G; Dimopoulos S; ; Meyer CH; Szurman GB
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):457-462. PubMed ID: 27632214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
    Kim M; Jeong S; Sagong M
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.